Still calculating financial ratios manually?
Stop wasting time — let the computer do it!
Enfusion, Inc. (ENFN) Financial Analysis and Rating
Comparison Analysis Based on SEC Data
| Company Name | Enfusion, Inc. |
| Industry (SIC) | 7372 - Prepackaged Software |
| Revenue in 2024 | $201,611 thousand (ranked #334 out of 512 companies in the industry) |
| Assets as of 12/31/2024 | $143,261 thousand (ranked #366) |
| Analyzed report | 12/31/2023 (filed 3/12/2024) |
Year:
Financial Position and Performance Annual | Quarterly
| Compared with Q4 2023 industry ratios | Change during the quarter |
|---|---|
|
much better |
unchanged |
| Compared with all listed companies |
|---|
|
much better |
Financial Ratios Benchmarking
| Financial Ratio | Comparison of company ratios for 12/31/2023 | ||
|---|---|---|---|
|
with Q4 2023 industry ratios (73 - Business Services) |
with all listed companies | ||
| Solvency Ratios | |||
| Debt ratio |
0.29
0.59
|
0.29
0.61
|
|
| Debt-to-equity ratio |
0.41
1.09
|
0.41
1.33
|
|
| Liquidity Ratios | |||
| Current Ratio |
3.44
1.49
|
3.44
1.72
|
|
| Quick Ratio |
3.14
1.17
|
3.14
1.04
|
|
| Cash Ratio |
1.75
0.59
|
1.75
0.53
|
|
| Profitability Ratios | |||
| Profit margin |
1.3%
-0.3%
|
1.3%
2.2%
|
|
| ROE (Return on equity), after tax |
3.2%
1.3%
|
3.2%
4.2%
|
|
| ROA (Return on assets) |
2.3%
-0.6%
|
2.3%
0.6%
|
|
| Activity Ratios | |||
| Asset turnover (days) |
211
545
|
211
711
|
|
| Receivables turnover (days) |
53
55
|
53
48
|
|
| Resulting score | +1,6 | +1,1 | |
Year:
Additional Ratios (not used in score calculation)
| Financial Ratio | Comparison of company ratios for 12/31/2023 | ||
|---|---|---|---|
|
with Q4 2023 industry ratios (73 - Business Services) |
with all listed companies | ||
| Profitability Ratios | |||
| Gross margin |
66.4%
58.1%
|
66.4%
40.6%
|
|
| Price Ratios | |||
| Earnings per Share (basic) | $0.01 | ||
| Earnings per Share (diluted) | $0.01 | ||
Auditor's Conclusion
We have performed a comparative analysis of the balance sheet and income statement of Enfusion, Inc. (hereafter – the "Company") for Q4 2023 as filed with the U.S. Securities and Exchange Commission (SEC). The primary business activity of the Company is "Prepackaged Software" (SIC code 7372). In our analysis, we compared the key financial ratios of the Company with the average (median) values of those ratios calculated for the Company's specific industry sector and for all companies. The averages were calculated using data from Q4 2023 financial statements filed with the SEC through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). By comparing each of the eleven key metrics to the median, we have reached an overall conclusion about the quality of the Company's financial condition. All calculations and conclusions were performed using software and methodologies developed by ReadyRatios.
Based on our analysis of the Company's key financial ratios, we have determined the following. The financial condition of Enfusion, Inc. in 2023 is much better than the typical financial condition of companies in the "Prepackaged Software" industry.
This conclusion is supported by a comparison of the Company's financial ratios with average U.S. ratios. The financial position of Enfusion, Inc. is much better than that of most listed companies that file financial statements with the U.S. Securities and Exchange Commission.